|
| |
Our
services
|
Helvetica Healthcare is a Swiss company made
up of international business development professionals who have held key
positions in leading multinational companies. The team has a vast
international experience and a proven track record in the fields of in
vitro diagnostics and human health care products, including a
comprehensive knowledge of the markets, international regulations and
the keys to successful tender bidding.
|
|
Helvetica Health Care maintains a worldwide network, which is constantly
expanded and developed, of distributors, direct clients and key
contacts, developed during many years of experience and frequent
missions throughout the world. All of these contacts represent potential
partners for companies wishing to undertake business abroad and recruit
international distributors for their products.
|
|
Helvetica Healthcare can provide everything from simple consultation on
how to set up an operation in your target markets, to the design and
implementation of a comprehensive sales and marketing plan to help you
realize your goals.
|
|
We offer training guidance services to your sales and marketing force
on how to approach and tackle challenging markets in your target market,
and can provide support from representative offices in the Middle East,
Asia and Latin America .
|
|
For start up companies we can provide you with an infrastructure that
can be immediately operational, as well as outlining a fully integrated
solution to your business needs. We can even help you to hire the right
Marketing and Sales team to help you get your business off the ground.
|
| |
|
NEWS
|
HHC is pleased to announce that a specific youtube page is now
available. This page will be implemented in the next months and
furnished with short movies presenting our products and relevant
scientific news.
|
HHC in association with Nucleon Ltd is taking part to the 20th UICC
World Cancer Congress from 27 to 31 Auust 2008 in Geneva. Through our
presence (stand n°1116) we will promote the advantages and benefits of
using
Cytoactiv the first prognostic marker for cervical dysplasia.
 |
|